Gilead Sciences, Inc. (GILD) Stock Forecast Nov. 6, 2026
Analysis updated on Nov. 6, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Gilead Sciences, Inc. (GILD) stock forecast summary
Our AI scores Gilead Sciences, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
Gilead Sciences, Inc. is a mega-cap company with a market capitalization of $207.84B. It ranks number 2 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast. Its Current Ratio of 1.38x is the lowest of the 59 peers that report one.
For GILD, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 18.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 14.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.9%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.2% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-30 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, GILD included.
GILD price chart and AI forecast
How GILD ranks among 4891 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Gilead Sciences, Inc. (GILD) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | GILD | Rank |
|---|---|---|
| Market Cap | $207.84B | 2/60 |
| P/B Ratio | 15.94x | 10/48 |
| Dividend Yield | 1.97% | – |
| EPS | $-3.15 | – |
| Book Value/Share | $10.51 | – |
| Revenue/Share | $24.98 | – |
| FCF/Share | $11.11 | – |
Profitability & Margins
| Metric | GILD | Rank |
|---|---|---|
| ROE | -29.6% | 21/44 |
| ROA | -7.5% | 15/47 |
| ROIC | -6.0% | 16/52 |
| Gross Margin | 79.9% | 8/24 |
| Operating Margin | -7.6% | 15/41 |
| Net Margin | -12.5% | 14/36 |
| EBT Margin | -8.2% | 16/43 |
| Tax Rate | -52.5% | – |
The effective tax rate is outside the normal band, which points to a large non-recurring tax item in the trailing twelve months; headline net income, net margin and P/E are affected by it.
Financial Health
| Metric | GILD | Rank |
|---|---|---|
| Current Ratio | 1.38x | 59/59 |
| Quick Ratio | 1.22x | 28/30 |
| D/E Ratio | 2.95x | 5/52 |
| Financial Leverage | 3.94x | 5/51 |
| Interest Coverage | 1.9x | 12/36 |
| Working Capital | $4.55B | 4/58 |
Cash Flow
| Metric | GILD | Rank |
|---|---|---|
| Operating Cash Flow | $14.48B | 2/56 |
| Free Cash Flow | $13.78B | 2/49 |
| Capital Spending | -$699M | 47/49 |
| OCF Growth YoY | 49.8% | 5/16 |
| FCF Growth YoY | 50.4% | 6/16 |
| FCF/Sales | 44.5% | 4/32 |
| CapEx/Sales | 2.3% | 23/32 |
Operational Efficiency
| Metric | GILD | Rank |
|---|---|---|
| Asset Turnover | 0.60x | 12/37 |
| Receivables Turnover | 6.2x | 11/23 |
| Inventory Turnover | 3.3x | 8/23 |
| Fixed Assets Turnover | 5.2x | 15/38 |
| Days Sales Outstanding | 59 days | 13/23 |
| Days Inventory | 111 days | 16/23 |
| Payables Period | 55 days | 16/26 |
| Cash Conversion Cycle | 115 days | 7/18 |
Income Statement
| Metric | GILD | Rank |
|---|---|---|
| Total Revenue | $30.99B | 2/38 |
| Operating Income | -$2.36B | 52/53 |
| Net Income | -$3.86B | 47/47 |
| R&D Expense | $6.33B | 3/55 |
| SG&A Expense | $6.81B | 2/23 |
| Cost of Goods Sold | $6.22B | 2/27 |
Dividend & Shareholder Information
| Metric | GILD | Rank |
|---|---|---|
| Dividends Per Share | $3.31 | – |
| Shares Outstanding | 1240M | – |
| Net Income Growth | -147.6% | 10/11 |
| EPS Growth | -148.8% | 13/15 |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $16.55B | 32.2% of assets |
| Cash & Short-term Investments | $6.44B | 12.5% of assets |
| Accounts Receivable | $5.01B | 9.7% of assets |
| Inventory | $1.90B | 3.7% of assets |
| Total Liabilities | $38.45B | 74.8% of assets |
| Short-term Debt | $11.07B | 21.5% of assets |
GILD quarterly financials and insider trading
Gilead Sciences, Inc. (GILD) industry peers
Companies classified under the same SEC industry code as Gilead Sciences, Inc. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| GILD Gilead Sciences, Inc. | $207.84B | |
| AMGN Amgen Inc | $248.84B | |
| MRNA Moderna, Inc. | $96.40B | |
| ARGX Argenx Se | $55.37B | |
| RVMD Revolution Medicines, Inc. | $38.08B | |
| BIIB Biogen Inc. | $36.06B | |
| BNTX Biontech Se | $21.71B | |
| EXEL Exelixis, Inc. | $16.77B | |
| NBIX Neurocrine Biosciences Inc | $16.24B | |
| HALO Halozyme Therapeutics, Inc. | $13.96B | |
| TECH Bio-Techne Corp | $11.41B | |
| QGEN Qiagen N.V. | $11.03B | |
| KYMR Kymera Therapeutics, Inc. | $10.94B | |
| RGEN Repligen Corp | $10.77B | |
| PCVX Vaxcyte, Inc. | $9.21B | |
| KRYS Krystal Biotech, Inc. | $8.90B | |
| IBRX Immunitybio, Inc. | $8.49B | |
| TWST Twist Bioscience Corp | $7.56B | |
| IMVT Immunovant, Inc. | $5.86B | |
| CGON Cg Oncology, Inc. | $5.74B | |
| KOD Kodiak Sciences Inc. | $5.72B | |
| SRRK Scholar Rock Holding Corp | $5.54B | |
| CRSP Crispr Therapeutics Ag | $4.70B | |
| ADPT Adaptive Biotechnologies Corp | $4.28B | |
| RLAY Relay Therapeutics, Inc. | $3.73B | |
| IOVA Iovance Biotherapeutics, Inc. | $3.51B | |
| TARS Tarsus Pharmaceuticals, Inc. | $3.33B | |
| DNLI Denali Therapeutics Inc. | $3.15B | |
| ADMA Adma Biologics, Inc. | $2.96B | |
| BEAM Beam Therapeutics Inc. | $2.67B | |
| RXRX Recursion Pharmaceuticals, Inc. | $2.18B | |
| COAG Hemab Therapeutics Holdings, Inc. | $2.13B | |
| VCEL Vericel Corp | $2.10B | |
| LIFE Atyr Pharma Inc | $2.08B | |
| BCRX Biocryst Pharmaceuticals Inc | $1.95B | |
| REPL Replimune Group, Inc. | $1.90B | |
| VIR Vir Biotechnology, Inc. | $1.86B | |
| MAZE Maze Therapeutics, Inc. | $1.81B | |
| MESO Mesoblast Ltd | $1.81B | |
| ALVO Alvotech | $1.62B | |
| NVAX Novavax Inc | $1.61B | |
| IMCR Immunocore Holdings Plc | $1.46B | |
| TSHA Taysha Gene Therapies, Inc. | $1.33B | |
| VOR Vor Biopharma Inc. | $1.15B | |
| CGEM Cullinan Therapeutics, Inc. | $1.01B | |
| ODTX Odyssey Therapeutics, Inc. | $907M | |
| GLUE Monte Rosa Therapeutics, Inc. | $874M | |
| IMTX Immatics N.V. | $829M | |
| MGTX Meiragtx Holdings Plc | $817M | |
| PRME Prime Medicine, Inc. | $807M | |
| SANA Sana Biotechnology, Inc. | $700M | |
| SLBT Sl Science Holding Ltd | $679M | |
| DNA Ginkgo Bioworks Holdings, Inc. | $671M | |
| SLDB Solid Biosciences Inc. | $663M | |
| AURA Aura Biosciences, Inc. | $657M | |
| FDMT 4d Molecular Therapeutics, Inc. | $621M | |
| DBVT Dbv Technologies S.A. | $616M | |
| CADL Candel Therapeutics, Inc. | $615M | |
| VALN Valneva Se | $551M | |
| ENTX Entera Bio Ltd. | $518M |
Where GILD sits on the market map
Gilead Sciences, Inc. (GILD) stock news
Loading...
Gilead Sciences, Inc. (GILD) stock forecast FAQ
What is the Gilead Sciences, Inc. (GILD) stock forecast?
Our AI scores Gilead Sciences, Inc. every trading day against every stock it covers. Create a free account and follow it to see its rating and price target.
How accurate are Gilead Sciences, Inc. stock predictions?
For GILD, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 18.0%, measured on 357 forecast dates between 2022-08-19 and 2026-08-07 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 14.0%, measured on 400 forecast dates between 2022-08-19 and 2026-10-07. Across our coverage, the out-of-sample test on 4629 stocks from 2025-01-06 to 2026-08-04 produced a positive net return in 92.9% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Gilead Sciences, Inc. forecasts updated?
Gilead Sciences, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Nov. 6, 2026.
Which companies are Gilead Sciences, Inc.'s industry peers?
60 issuers in our coverage, GILD included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB), Biontech Se (BNTX).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.